probenecid has been researched along with Urinary Lithiasis in 1 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Stamp, L | 1 |
Dalbeth, N | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept[NCT04012294] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-08-30 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for probenecid and Urinary Lithiasis
Article | Year |
---|---|
Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution.
Topics: Allopurinol; Asymptomatic Diseases; Drug Eruptions; Drug Hypersensitivity; Febuxostat; Gout Suppress | 2017 |